Jinyang Gu
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation (NCT04415567) | Jinyang Gu | 2018-06-01 |
Track Jinyang Gu automatically
Every clearance here is in the API, with alerts when new ones post.